Consensus Candel Therapeutics, Inc.

Equities

CADL

US1374041093

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			After market 06:19:06 pm
9.32 ^USD	-6.52%		9.295	-0.27%

Apr. 11	Sector Update: Health Care Stocks Decline Thursday Afternoon	MT
Apr. 11	Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug	MT

Evolution of the average Target Price on Candel Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3f4202a4f468c134159338.FcWFJavhj3b-GdBGOFVgxqkE65uQBMqkKrCxg9IbetI.XIGxEsmR_BO3bIUZCmM0o9hntNL4cLn1H_LS9eJ_CroiqrVDw6DOGK9ImQ~25df243d729c871c789042a546d16c60

Analyst Recommendations on Candel Therapeutics, Inc.

Credit Suisse Trims Candel Therapeutics' Price Target to $7 From $8, Updates Model to Reflect Q4 Actuals; Keeps Outperform Rating	23-03-31	MT
UBS Adjusts Candel Therapeutics Price Target to $8 From $11, Maintains Buy Rating	22-12-09	MT
Credit Suisse Lowers Candel Therapeutics' Price Target to $8 From $10, Keeps Outperform Rating	22-12-07	MT
HC Wainwright Starts Candel Therapeutics at Buy With $11 Price Target	22-12-02	MT
BMO Capital Adjusts Candel Therapeutics' Price Target to $12 from $18, Keeps Outperform Rating	22-03-31	MT
BMO Initiates Candel Therapeutics With Outperform Rating, $18 Price Target	21-11-18	MT
Candel Therapeutics : Shares Rise After Analyst Recommendations	21-08-23	MT
CANDEL THERAPEUTICS : Credit Suisse Starts Candel Therapeutics at Outperform with $15 PT, Notes Potential for Improved Investor Sentiment, Valuation	21-08-23	MT
CANDEL THERAPEUTICS : UBS Starts Candel Therapeutics at Buy With $9 Price Target	21-08-23	MT
CANDEL THERAPEUTICS : Jefferies Starts Candel Therapeutics at Buy With $22 Price Target	21-08-23	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.32 USD

Average target price

11 USD

Spread / Average Target

+18.03%

High Price Target

11 USD

Spread / Highest target

+18.03%

Low Price Target

11 USD

Spread / Lowest Target

+18.03%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Candel Therapeutics, Inc.

Credit Suisse
UBS
HC Wainwright
BMO Capital
Jefferies & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar